---
title: "Cardio Diagnostics Holdings, Inc. (CDIO.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/CDIO.US.md"
symbol: "CDIO.US"
name: "Cardio Diagnostics Holdings, Inc."
industry: "生物技术"
---

# Cardio Diagnostics Holdings, Inc. (CDIO.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [cdio.ai](https://cdio.ai) |

## Company Profile

Cardio Diagnostics Holdings, Inc. 开发和商业化基于表观遗传学的心血管疾病临床检测。该公司提供 Epi+Gen CHD，这是一项为期三年的冠心病（CHD）症状风险评估临床血液检测，针对包括心脏病发作在内的冠心病事件；PrecisionCHD，这是一项综合的表观遗传 - 遗传临床血液检测，用于检测冠心病；以及可操作的临床智能平台，提供新的表观遗传和遗传见解，帮助临床医生改善慢性病管理。它还提供 CardioInnovate360，这是一种仅供研究使用的解决方案，支持新型生物制药的发现、开发和验证，以评估和管理心血管疾病；以及 HeartRisk，这是一种 SaaS...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-19T04:30:15.000Z

**Overall: D (0.64)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 332 / 402 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -55.78% |  |
| Net Profit YoY | 20.61% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.48 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3.89M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 15782.00 |  |


**Multi Score**: D

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -110.70% | E |
| Profit Margin | -41516.33% | E |
| Gross Margin | 100.00% | A |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -55.78% | E |
| Net Profit YoY | 20.61% | B |
| Total Assets YoY | 96.12% | A |
| Net Assets YoY | 121.14% | A |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -0.24% | D |
| OCF YoY | -55.78% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 7.25% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Cardio Diagnostics Holdings, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-110.70%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-41516.33%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "100.00%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-55.78%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "20.61%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "96.12%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "121.14%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-0.24%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-55.78%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "7.25%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制药 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | OpGen (US.OPGN) | B | A | A | A | B | A |
| 05 | 艾伯维 (US.ABBV) | A | C | E | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.59 | 152/603 | - | - | - |
| PB | 0.48 | 34/603 | 1.80 | 0.69 | 0.59 |
| PS (TTM) | 246.45 | 280/603 | 464.59 | 359.73 | 321.50 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-01-24T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.13 |

## References

- [Company Overview](https://longbridge.com/en/quote/CDIO.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/CDIO.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/CDIO.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.